HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model

References

• Adams PD, Afonine PV, Bunkoczi G, et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D: Biol Crystallogr 66:213–21.
   PubMed Web of Science ®Google Scholar
• Adigun RA, Martincigh B, Nyamori VO, et al. (2014). Kinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazoleruthenate(III)], NAMI-A, by 2-mercaptoethane sulfonate. Dalton Trans 43:12943–51.
   PubMed Web of Science ®Google Scholar
• Aw MS, Kurian M, Losic D. (2013). Polymeric micelles for multidrug delivery and combination therapy. Chemistry 19:12586–601.
   PubMed Web of Science ®Google Scholar
• Baguley BC. (2010). Multidrug resistance in cancer. Methods Mol Biol 596:1–14.
   PubMedGoogle Scholar
• Bao Y, Yin M, Hu X, et al. (2016). A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery. J Control Release 235:182–94.
   PubMed Web of Science ®Google Scholar
• Beraldo H, Gambino D. (2004). The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes. Mini Rev Med Chem 4:31–9.
   PubMed Web of Science ®Google Scholar
• Bergamo A, Riedel T, Dyson PJ, et al. (2015). Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer. Invest New Drugs 33:53–63.
   PubMed Web of Science ®Google Scholar
• Bergamo A, Sava G. (2015). Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chem Soc Rev 44:8818–35.
   PubMed Web of Science ®Google Scholar
• Cao X, Luo J, Gong T, et al. (2015). Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol Pharm 12:274–86.
   PubMed Web of Science ®Google Scholar
• Chavanpatil MD, Khdair A, Gerard B, et al. (2007). Surfactant–polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm 4:730–8.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang Y, Yao Y, et al. (2017). Sequential delivery of Cyclopeptide RA-V and Doxorubicin for combination therapy on resistant tumor and in situ monitoring of Cytochrome c release. Theranostics 7:3781–93.
   PubMed Web of Science ®Google Scholar
• Curry S, Mandelkow H, Brick P, et al. (1998). Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 5:827–35.
   PubMed Web of Science ®Google Scholar
• DeLano WL. (2004). The PyMol molecular graphics system. San Carlos (CA): DeLano ScientiWc.
   Google Scholar
• Du C, Deng D, Shan L, et al. (2013). A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials 34:3087–97.
   PubMed Web of Science ®Google Scholar
• Ferraro G, Massai L, Messori L, et al. (2015). Cisplatin binding to human serum albumin: a structural study. Chem Commun (Camb) 51:9436–9.
   PubMed Web of Science ®Google Scholar
• Furukawa M, Tanaka R, Chuang VT, et al. (2011). Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury. J Control Release 154:189–95.
   PubMed Web of Science ®Google Scholar
• Gandin V, Porchia M, Tisato F, et al. (2013). Novel mixed-ligand copper(I) complexes: role of diimine ligands on cytotoxicity and genotoxicity. J Med Chem 56:7416–30.
   PubMed Web of Science ®Google Scholar
• Garmann D, Warnecke A, Kalayda GV, et al. (2008). Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. J Control Release 131:100–6.
   PubMed Web of Science ®Google Scholar
• Gou Y, Qi J, Ajayi JP, et al. (2015a). Developing Anticancer Copper(II) pro-drugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain. Mol Pharm 12:3597–609.
   PubMed Web of Science ®Google Scholar
• Gou Y, Yang F, Liang H. (2016a). Designing prodrugs based on special residues of human serum albumin. Curr Top Med Chem 16:996–1008.
   PubMed Web of Science ®Google Scholar
• Gou Y, Zhang Y, Qi J, et al. (2016b). Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer. Oncotarget 7:67004–19.
   PubMed Web of Science ®Google Scholar
• Gou Y, Zhang Y, Yang F, et al. (2015b). Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs. Curr Pharm Des 21:1848–61.
   PubMed Web of Science ®Google Scholar
• Gou Y, Zhang Y, Zhang Z, et al. (2017). Design of an anticancer Copper(II) prodrug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier. Mol Pharm 14:1861–73.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.
   PubMed Web of Science ®Google Scholar
• Greco F, Vicent MJ. (2009). Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 61:1203–13.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144:646–74.
   PubMed Web of Science ®Google Scholar
• Hanif M, Nazarov AA, Legin A, et al. (2012). Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. Chem Commun (Camb) 48:1475–7.
   PubMed Web of Science ®Google Scholar
• Huang P, Wang D, Su Y, et al. (2014). Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J Am Chem Soc 136:11748–56.
   PubMed Web of Science ®Google Scholar
• Huang W, Chen L, Kang L, et al. (2017). Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs. Adv Drug Deliv Rev 115:82–97.
   PubMed Web of Science ®Google Scholar
• Iversen T-G, Skotland T, Sandvig K. (2011). Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6:176–85.
   Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, et al. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11:812–18.
   PubMed Web of Science ®Google Scholar
• Kayani Z, Firuzi O, Bordbar AK. (2018). Doughnut-shaped bovine serum albumin nanoparticles loaded with doxorubicin for overcoming multidrug-resistant in cancer cells. Int J Biol Macromol. 107:1835–43
   PubMed Web of Science ®Google Scholar
• Kratz F. (2007). DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs 16:855–66.
   PubMed Web of Science ®Google Scholar
• Kratz F. (2008). Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–83.
   PubMed Web of Science ®Google Scholar
• Kratz F. (2014). A clinical update of using albumin as a drug vehicle – a commentary. J Control Release 190:331–6.
   PubMed Web of Science ®Google Scholar
• Kratz F, Elsadek B. (2012). Clinical impact of serum proteins on drug delivery. J Control Release 161:429–45.
   PubMed Web of Science ®Google Scholar
• Krojer T, Talon R, Pearce N, et al. (2017). The XChemExplorer graphical workflow tool for routine or large-scale protein-ligand structure determination. Acta Crystallogr D: Struct Biol 73:267–78.
   PubMedGoogle Scholar
• Kurapati R, Raichur AM. (2012). Graphene oxide based multilayer capsules with unique permeability properties: facile encapsulation of multiple drugs. Chem Commun (Camb) 48:6013–15.
   PubMed Web of Science ®Google Scholar
• Li W, Guo X, Kong F, et al. (2017). Overcoming photodynamic resistance and tumor targeting dual-therapy mediated by indocyanine green conjugated gold nanospheres. J Control Release 258:171–81.
   PubMed Web of Science ®Google Scholar
• Liu S, Guo Y, Huang R, et al. (2012). Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 33:4907–16.
   PubMed Web of Science ®Google Scholar
• Ma L, Kohli M, Smith A. (2013). Nanoparticles for combination drug therapy. ACS Nano 7:9518–25.
   PubMed Web of Science ®Google Scholar
• Maeda H, Sawa T, Konno T. (2001). Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47–61.
   PubMed Web of Science ®Google Scholar
• Mizutani H, Oikawa S, Hiraku Y, et al. (2003). Distinct mechanisms of site-specific oxidative DNA damage by doxorubicin in the presence of copper(II) and NADPH-cytochrome P450 reductase. Cancer Sci 94:686–91.
   PubMed Web of Science ®Google Scholar
• Otwinowski Z, Minor W. (1997). Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307–26.
   PubMed Web of Science ®Google Scholar
• Parhi P, Mohanty C, Sahoo SK. (2012). Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 17:1044–52.
   PubMed Web of Science ®Google Scholar
• Park KC, Fouani L, Jansson PJ, et al. (2016). Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics. Metallomics: Integrated Biometal Sci 8:874–86.
   PubMed Web of Science ®Google Scholar
• Qi J, Gou Y, Zhang Y, et al. (2016a). Developing anticancer ferric prodrugs based on the N-donor residues of human serum albumin carrier IIA subdomain. J Med Chem 59:7497–511.
   PubMed Web of Science ®Google Scholar
• Qi J, Zhang Y, Gou Y, et al. (2016b). Multidrug delivery systems based on human serum albumin for combination therapy with three anticancer agents. Mol Pharm 13:3098–105.
   PubMed Web of Science ®Google Scholar
• Qi J, Zhang Y, Gou Y, et al. (2016c). Developing an anticancer Copper(II) pro-drug based on the His242 residue of the human serum albumin carrier IIA subdomain. Mol Pharm 13:1501–7.
   PubMed Web of Science ®Google Scholar
• Ruiz-Azuara L, Bravo-Gomez ME. (2010). Copper compounds in cancer chemotherapy. Curr Med Chem 17:3606–15.
   PubMed Web of Science ®Google Scholar
• Santini C, Pellei M, Gandin V, et al. (2014). Advances in copper complexes as anticancer agents. Chem Rev 114:815–62.
   PubMed Web of Science ®Google Scholar
• Sava G, Capozzi I, Clerici K, et al. (1998). Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis 16:371–9.
   PubMed Web of Science ®Google Scholar
• Sava G, Zorzet S, Turrin C, et al. (2003). Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res 9:1898–905.
   PubMed Web of Science ®Google Scholar
• Seebacher N, Lane DJ, Richardson DR, et al. (2016). Turning the gun on cancer: utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. Free Radic Biol Med 96:432–45.
   PubMed Web of Science ®Google Scholar
• Shen WC, Ryser HJ. (1981). cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Biophys Res Commun 102:1048–54.
   PubMed Web of Science ®Google Scholar
• Simard JR, Zunszain PA, Ha CE, et al. (2005). Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci USA 102:17958–63.
   PubMed Web of Science ®Google Scholar
• Simard JR, Zunszain PA, Hamilton JA, et al. (2006). Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol 361:336–51.
   PubMed Web of Science ®Google Scholar
• Stehle G, Wunder A, Sinn H, et al. (1997). Pharmacokinetics of methotrexate–albumin conjugates in tumor-bearing rats. Anticancer Drugs 8:835–44.
   PubMed Web of Science ®Google Scholar
• Torchilin V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–5.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. (2015). Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yu F, Huang S, et al. (2015). The macromolecular crystallography beamline of SSRF. Nucl Sci Technol 26:010102.
   Web of Science ®Google Scholar
• Wang Z, Li X, Wang D, et al. (2017). Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles. Acta Biomater 62:144–56.
   PubMed Web of Science ®Google Scholar
• Webb MI, Wu B, Jang T, et al. (2013). Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions. Chem Eur J 19:17031–42.
   PubMed Web of Science ®Google Scholar
• Wong HL, Bendayan R, Rauth AM, et al. (2006). A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 317:1372–81.
   PubMed Web of Science ®Google Scholar
• Yan Y, Such GK, Johnston AP, et al. (2012). Engineering particles for therapeutic delivery: prospects and challenges. ACS Nano 6:3663–9.
   PubMed Web of Science ®Google Scholar
• Yang C, Wu T, Qi Y, et al. (2018). Recent advances in the application of vitamin E TPGS for drug delivery. Theranostics 8:464–85.
   PubMed Web of Science ®Google Scholar
• Yang F, Liang H. (2015). Editorial: HSA-based drug development and drug delivery systems. Curr Pharm Des 21:1784.
   PubMed Web of Science ®Google Scholar
• Yang F, Ma ZY, Zhang Y, et al. (2013). Human serum albumin-based design of a diflunisal prodrug. Eur J Pharm Biopharm 84:549–54.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Lee EA, Park TG. (2002). Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release 82:17–27.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ho A, Yue J, et al. (2014). Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin. Eur J Med Chem 86:449–55.
   PubMed Web of Science ®Google Scholar
• Zsila F. (2013). Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model. Mol Pharm 10:1668–82.
   PubMed Web of Science ®Google Scholar